SCHEMBL952323

SCHEMBL952323

Cc1nn2ccccc2c1-c1nc(C2CCOCC2)c(C(=O)O)s1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 2/20 0.39
CHEK1 O14757 1/20 0.37
ATR Q13535 1/20 0.37
PDCD1 Q15116 1/20 0.37
ATRIP Q8WXE1 1/20 0.37
CD274 Q9NZQ7 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.36
TSHR P16473 1/20 0.35
PDE4B Q07343 2/20 0.35
MAPK9 P45984 1/20 0.35
MAPK10 P53779 1/20 0.35
PDE10A Q9Y233 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.34
PIK3CD O00329 1/20 0.34
PIK3CA P42336 1/20 0.34
PIK3CB P42338 1/20 0.34
HTR2C P28335 1/20 0.34
KDM4E B2RXH2 1/20 0.33
KMT2A Q03164 1/20 0.33
VCP P55072 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL953761 0.91 CHEK1 (0.36) CNR1CHEK1ATRPDCD1ATRIP
SCHEMBL955453 0.90 TSHR (0.42) CNR1SMN1; SMN2TSHRPDE4BMAPK9
SCHEMBL954029 0.88 ALDH1A1 (0.42) CHEK1ATRPDCD1ATRIPCD274
SCHEMBL953958 0.81 TSHR (0.42) CNR1SMN1; SMN2TSHRPDE4BMAPK9
SCHEMBL953767 0.78 TSHR (0.43) TSHRKDM4E
SCHEMBL16937941 0.77 CHEK1 (0.35) CHEK1ATRPDCD1ATRIPCD274
SCHEMBL953113 0.77 CDC7 (0.50) SMN1; SMN2KDM4EKMT2A
SCHEMBL6842656 0.77 CHEK1 (0.34) CHEK1ATRPDCD1ATRIPCD274
SCHEMBL957604 0.77 CHEK1 (0.33) CHEK1ATRPDCD1ATRIPCD274
SCHEMBL954624 0.76 SMN1; SMN2 (0.44) CNR1SMN1; SMN2KDM4EKMT2AVCP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9139589-B2 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2015-09-22 US disclosed
US-9090601-B2 Thiazole derivatives MILLENNIUM PHARMACEUTICALS, INC. (US) 2015-07-28 US disclosed
EP-2391619-A1 HETEROARYLS AND THEIR USE AS PI3K INHIBITORS Millennium Pharmaceuticals, Inc. (US) 2011-12-07 EP disclosed
US-20110003807-A1 Thiazole derivatives MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-01-06 US disclosed
US-20110003806-A1 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-01-06 US disclosed
WO-2010090716-A1 HETEROARYLS AND THEIR USE AS PI3K INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2010-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003807-A1 Thiazole derivatives MTOR, RICTOR, AKT2 CNR1 3484/4885CHEK1 812/4885ATR 1442/4885
US-20110003806-A1 Heteroaryls and uses thereof RICTOR, MTOR, AKT1S1 CNR1 290/4885CHEK1 913/4885ATR 2022/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.